Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1]
It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.[2]
- Market Cap ₹ 1,13,372 Cr.
- Current Price ₹ 3,351
- High / Low ₹ 3,591 / 2,870
- Stock P/E 59.2
- Book Value ₹ 224
- Dividend Yield 0.95 %
- ROCE 27.0 %
- ROE 26.5 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company has been maintaining a healthy dividend payout of 42.6%
Cons
- Stock is trading at 14.9 times its book value
- The company has delivered a poor sales growth of 7.72% over past five years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare BSE 200 Nifty Next 50 Nifty 500
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4,172 | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | |
3,216 | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,795 | |
Operating Profit | 955 | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,721 |
OPM % | 23% | 22% | 41% | 24% | 23% | 26% | 27% | 31% | 29% | 30% | 31% | 32% |
34 | 286 | 32 | 223 | 299 | -300 | 121 | 57 | -288 | 45 | 146 | -1 | |
Interest | 59 | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 333 | 354 | 252 |
Depreciation | 87 | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 707 | 808 | 795 |
Profit before tax | 844 | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,673 |
Tax % | 21% | 20% | 26% | 14% | 27% | 22% | 14% | 18% | 37% | 33% | 30% | 28% |
664 | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | |
EPS in Rs | 19.62 | 22.19 | 51.22 | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 56.47 |
Dividend Payout % | 25% | 25% | 34% | 25% | 35% | 66% | 53% | 47% | 105% | 60% | 57% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 8% |
3 Years: | 11% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 14% |
3 Years: | 21% |
TTM: | 21% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | 23% |
3 Years: | 32% |
1 Year: | 14% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 23% |
3 Years: | 24% |
Last Year: | 27% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 |
Reserves | 1,818 | 2,406 | 3,409 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,421 |
1,132 | 2,740 | 2,352 | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 5,369 | 4,022 | 3,202 | |
1,988 | 2,589 | 3,040 | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,043 | 3,627 | 3,603 | |
Total Liabilities | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 |
875 | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,121 | 8,138 | 7,947 | |
CWIP | 534 | 678 | 1,042 | 519 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 478 |
Investments | 186 | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 156 |
3,427 | 4,011 | 4,206 | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,524 | 5,834 | 5,815 | |
Total Assets | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
599 | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 | 2,585 | |
-418 | -2,113 | -869 | -798 | -4,677 | -246 | 229 | -444 | -196 | -2,335 | -160 | -549 | |
86 | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | 77 | -2,780 | -2,298 | |
Net Cash Flow | 268 | -90 | 437 | 18 | -366 | 238 | 73 | -89 | -174 | 110 | 327 | -262 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 96 | 125 | 79 | 60 | 77 | 68 | 76 | 69 | 70 | 74 | 63 | 59 |
Inventory Days | 297 | 275 | 314 | 318 | 429 | 318 | 362 | 456 | 368 | 298 | 310 | 334 |
Days Payable | 421 | 472 | 523 | 356 | 447 | 345 | 345 | 351 | 250 | 224 | 284 | 239 |
Cash Conversion Cycle | -28 | -71 | -130 | 21 | 59 | 42 | 93 | 174 | 188 | 147 | 89 | 154 |
Working Capital Days | 42 | 54 | -1 | 28 | 20 | -17 | -2 | 82 | 89 | 74 | 53 | 66 |
ROCE % | 35% | 27% | 48% | 19% | 13% | 13% | 15% | 17% | 19% | 20% | 23% | 27% |
Documents
Announcements
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 ('Listing Regulations') Letter To Shareholders - Integrated Annual Report FY 2024-25
1d - Notice and Annual Report for FY 2024-25 shared with shareholders via web link for AGM on 28 July 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 Jul - Newspaper Advertisement in respect of AGM and E-voting procedure
-
Business Responsibility and Sustainability Reporting (BRSR)
4 Jul - Torrent Pharma submits FY 2024-25 Business Responsibility and Sustainability Report with ESG disclosures and assurance.
- Reg. 34 (1) Annual Report. 4 Jul
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
3 Jul - Torrent Pharma to acquire controlling stake in J.B. Chemicals; buys 2.41% shares for INR 620 crore.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
Jun 2025TranscriptNotesPPT
-
May 2025TranscriptPPT
-
Jan 2025TranscriptPPT
-
Oct 2024TranscriptPPTREC
-
Jul 2024TranscriptPPT
-
May 2024TranscriptPPT
-
Feb 2024TranscriptPPT
-
Aug 2023TranscriptPPT
-
May 2023TranscriptPPT
-
Sep 2022TranscriptNotesPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018TranscriptPPT
-
May 2018TranscriptNotesPPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Oct 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
May 2016TranscriptPPT
Product Segments Q2 FY25
1) Branded Generics (74%): [1] The company’s branded generics business focuses on the manufacturing pharmaceutical products under its brand names catering to various therapeutic segments including cardiovascular, central nervous system, gastrointestinal, vitamin mineral nutrients, dermatology, diabetes, pain management and gynecology. Its branded generic medicines are marketed in key regions including India and Brazil. [2]